A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

Table 5 First Generation INSTIs: Selected drug-related adverse events after week 48 recorded in 2% or more patients in either treatment group

	Raltegravir(RAL + FTC/TDF)				Elvitegravir(EVG/COBI/FTC/TDF)
	STARTMRK^a		ONCEMRK^a		GS-236-0102^b		GS-236-0103^b		GS-292–0104/0111^d
Adverse Reaction	RAL n = 281	EFV n = 282	RAL 1200 mg QD n = 531	RAL 400 mg BID n = 266	EVG/ COBI FTC/ TDF n = 348	EFV/ FTC/ TDF n = 352	EVG/ COBI/ FTC/ TDF n = 353	ATV/ RTV + FTC/ TDF n = 355	EVG/ COBI/ FTC/ TAF N = 866	EVG/ COBI/ FTC/ TDF N = 867
Diarrhea	1%	3%	2%	3%	23%	19%	22%	27%	17%	19%
Nausea	3%	4%	7%	7%	21%	14%	20%	19%	15%	17%
Vomiting	-	-	2%	1%	-	-	-	-	7%	6%
Fatigue	1%	3%	-	-	11%	13%	14%	13%	8%	8%
Upper respiratory infection	-	-	-	-	14%	11%	15%	16%	11%	13%
Dizziness	1%	6%	2%	3%	7%	24%	-	-	5%	4%
Headache	4%	5%	3%	5%	14%	10%	15%	12%	14%	13%
Insomnia	4%	3%	-	-	9%	14%	-	-	7%	6%
Depression	-	-	-	-	9%	11%	-	-	-	-
Rash	-	-	-	-	6%	12%	-	-	6%	5%
Discontinuations due to drug-related clinical adverse events	1%	4%	0%	1%	4%^c	5%^c	4%^c	5%^c	1%	1%
References	[90]		[63]		[91]		[11]		[65]

Dash (-) indicates that information regarding this adverse effect was not reported in the study results
ATV atazanavir, COBI cobicistat, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, RAL raltegravir, RTV ritonavir, TDF tenofovir disoproxil fumarate
^aReported as drug-related clinical adverse events of moderate-severe intensity
^bReported as adverse events in ≥ 10% of patients in either group
^cDiscontinuations reported as patients with any treatment-emergent adverse event leading to premature discontinuation of study drug; whether they were deemed to be drug-related was not distinguished
^dReported as adverse events in ≥ 5% of patients in either group

ISSN: 1742-4690